Attached files
| file | filename |
|---|---|
| EX-5.1 - EXHIBIT 5.1 - AVENUE THERAPEUTICS, INC. | v467022_ex5-1.htm |
| EX-10.3 - EXHIBIT 10.3 - AVENUE THERAPEUTICS, INC. | v467022_ex10x3.htm |
| EX-1.1 - EXHIBIT 1.1 - AVENUE THERAPEUTICS, INC. | v467022_ex1-1.htm |
| S-1/A - S-1/A - AVENUE THERAPEUTICS, INC. | v467022_s1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Avenue Therapeutics, Inc.
New York, New York
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 6, 2017, except for Note 11 which is as of May 15, 2017, relating to the financial statements of Avenue Therapeutics, Inc., which is contained in that prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/BDO USA, LLP
Boston, Massachusetts
May 19, 2017